Tom McKillop Quotes (5 Quotes)

The history of this division, partly because of the devices element, is that reviews and approvals tend to be very slow, so we made realistic to conservative assumptions on what the review period should be.

A continued strong sales performance, especially for the five key growth products, together with benefits arising from productivity initiatives across the entire company, has produced an outstanding result ... and is reflected in an increase in our financial targets for the full year.

We will have 14 new candidate drugs in development this year, so that's a really excellent performance,

We are big enough at this stage to grow our business strongly. I am not ruling out what you may describe as bolt-on acquisitions -- what I am ruling out is a significant merger or anything like that.

The typical review time in this division, the period to approval, is something like two years,